相关实验视频

Updated: Jul 4, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Cdc42驱动的内体胆固醇运输促进了HER2阳性胃癌中的附带抗性

Bishan Liang¹, Qijing Wu¹, Yawen Wang¹

¹Department of Oncology, Nanfang Hospital, Southern Medical University, 510515, Guangzhou, Guangdong, China.

|February 9, 2024

概括

在HER2阳性胃癌中对trastuzumab的耐药性会导致对化疗的附带耐药性. 抑制Cdc42可能会扭转这种情况,提供新的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

特拉斯图祖马布耐药性是HER2阳性胃癌 (GC) 的一个主要挑战.
对他斯图祖马布耐药性对其他药物的敏感性的影响尚不清楚.
了解药物相互作用对于有效的治疗选择和患者生存至关重要.

研究的目的:

为了绘制抗祖马布耐药HER2阳性GC的药物敏感性概况.
阐明驱动附带电阻的机制.
识别潜在的治疗目标,以克服抗药性.

主要方法:

使用了耐特苏祖马布的GC细胞系和患者组织样本.
开发了一种13基因的评分模型来识别附带抗性.
研究了内分体胆固醇运输和-ABCB1轴的作用.
研究了Cdc42在胆固醇运输和抵抗中的功能.
在体外和体内使用ZCL278测试了Cdc42抑制的有效性.

主要成果:

特拉斯图祖马布耐药性诱导HER2阳性GC中对化疗的附带耐药性.
一个13基因模型预测了耐药患者的不良预后和对降胆固醇药物的敏感性.
通过NPC1-TβRI-Cdc42复合体的内体胆固醇运输丰富了血膜胆固醇,驱动了抵抗力.
使用ZCL278抑制Cdc42激活可以降低胆固醇,并逆转附带抗性.

结论:

在GC中特拉斯图祖马布耐药性与通过胆固醇运输的化疗耐药性有机联系.
Cdc42是这种附带电阻的关键媒介.
准Cdc42激活是一种有前途的治疗策略,用于对抗沙特祖马布耐药HER2阳性GC的二线治疗.

关键词:

Cdc42 在线播放胆固醇重编程是可以重编程的.抵押品的抵制力是抵押品的抵制力.胃癌是什么?胃癌是什么?这就是Trastuzumab.

更多相关视频

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Combined Conditional Knockdown and Adapted Sphere Formation Assay to Study a Stemness-Associated Gene of Patient-derived Gastric Cancer Stem Cells

Combined Conditional Knockdown and Adapted Sphere Formation Assay to Study a Stemness-Associated Gene of Patient-derived Gastric Cancer Stem Cells

Published on: May 9, 2020

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Receptor Downregulation in MVBs

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...